

Formulary Updates for Standard Control with Advanced Control Specialty Formulary® effective January 1, 2027

Products to be **added** to the formulary:

Formulary Additions

Drug Class	Product(s) Added
Anti-infectives, Hepatitis C	MAVYRET
Antineoplastic Agents, Biosimilars	OGIVRI, TRUXIMA
Antineoplastic Agents, Monoclonal Antibodies	PERJETA (Non-preferred)
Autoimmune Agents, Physician-Administered	INFLIXIMAB^
Cardiovascular, Antilipemics	<i>icosapent ethyl</i> , LIPFENDRA^
Central Nervous System, Antidepressants	AUVELITY TITRATION PACK^
Endocrine and Metabolic, Calcium Regulators	BILPREVDA^
Endocrine and Metabolic, Diabetic Supplies	FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING SYSTEM
Endocrine and Metabolic, Growth Improvement Agents	YUVIWEL^
Endocrine and Metabolic, Menopausal Symptom Agents	<i>estradiol vaginal tablet</i> , Yuvaferm
Gastrointestinal, Inflammatory Bowel Disease	<i>budesonide ext-rel tablet</i>
Ophthalmic, Dry Eye Disease	<i>cyclosporine ophthalmic emulsion 0.05%</i> , MIEBO^
Topical, Dermatology, Rosacea	<i>doxycycline monohydrate delayed-rel capsule</i>

These products will move **from non-preferred to preferred**:

Tier Changes: Non-Preferred to Preferred

Drug Class	Product Name(s)
Immunologic Agents, Immunosuppressants	BENLYSTA

Products that will be **removed** from the formulary:

Formulary Removals

Drug Class	Removed Product(s)	Formulary Options
Anti-infectives, Hepatitis C	EPCLUSA, HARVONI, SOVALDI, VOSEVI	MAVYRET
Antineoplastic Agents, Biologic Response Modifiers	POMALYST*	<i>pomalidomide</i>
Antineoplastic Agents, Biosimilars	KANJINTI	OGIVRI, TRAZIMERA
	RUXIENCE	TRUXIMA
Antineoplastic Agents, Kinase Inhibitors	BOSULIF*	<i>bosutinib, dasatinib, imatinib mesylate, nilotinib, SCEMBLIX</i>
Autoimmune Agents, Self-Administered	VELSIPITY	<u>Ulcerative Colitis</u> : <i>tofacitinib ext-rel</i> , ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ENTYVIO SC, HYRIMOZ (by Cordavis), PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, YESINTEK SC, ZEPOSIA
Cardiovascular, Antilipemics	VASCEPA*	<i>icosapent ethyl, omega-3 acid ethyl esters</i>
Cardiovascular, Heart Failure	CORLANOR*	<i>ivabradine</i>
	ENTRESTO*	<i>sacubitril-valsartan</i>
	VERQUVO	<i>dapagliflozin, ivabradine, sacubitril-valsartan, JARDIANCE, KERENDIA</i>
Cardiovascular, Pulmonary Arterial Hypertension	OPSUMIT*	<i>ambrisentan, bosentan, macitentan</i>
Central Nervous System, Multiple Sclerosis Agents	PONVORY	<i>dimethyl fumarate delayed-rel, fingolimod, glatiramer, teriflunomide</i> , AVONEX, BAFIERTAM, BETASERON, BRIUMVI, KESIMPTA, MAYZENT, OCREVUS, REBIF, TYRUKO, VUMERITY, ZEPOSIA
Endocrine and Metabolic, Diabetic Supplies	DEXCOM CONTINUOUS GLUCOSE MONITORING SYSTEM	FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING SYSTEM
Endocrine and Metabolic, Menopausal Symptom Agents	VAGIFEM*	<i>estradiol vaginal cream, estradiol vaginal tablet, Yuvafem, IMVEXXY</i>

Drug Class	Removed Product(s)	Formulary Options
Gastrointestinal, Inflammatory Bowel Disease	UCERIS*	<i>balsalazide, budesonide ext-rel tablet, mesalamine delayed-rel, mesalamine ext-rel, sulfasalazine, sulfasalazine delayed-rel</i>
Gastrointestinal, Irritable Bowel Syndrome	TRULANCE	<i>lubiprostone, prucalopride, LINZESS</i>
Ophthalmic, Dry Eye Disease	RESTASIS SINGLE DOSE*	<i>cyclosporine ophthalmic emulsion 0.05%, MIEBO, RESTASIS MULTIDOSE, VEVYE</i>
Respiratory, Steroid Inhalants	<i>fluticasone furoate ellipta</i>	ASMANEX HFA, PULMICORT FLEXHALER
Topical, Dermatology, Rosacea	ORACEA*	<i>doxycycline monohydrate delayed-rel capsule</i>

These products will move **from preferred to non-preferred:**

Tier Changes: Preferred to Non-Preferred

Drug Class	Product Name(s)	Formulary Options
Anti-infectives, Antiretroviral Combination Agents	DESCOVY	<i>emtricitabine-tenofovir disoproxil fumarate, APRETUDE, CIMDUO, YEZTUGO</i>
Cardiovascular, Beta-Blockers	LOPRESSOR*	<i>metoprolol tartrate</i>
Endocrine and Metabolic, Human Growth Hormones	HUMATROPE	NORDITROPIN, SOGROYA
Ophthalmic, Sympathomimetics	ALPHAGAN P*	<i>brimonidine ophthalmic solution</i>

UPPERCASE represents brand products
lowercase represents generic products

^Previously New to Market Block
 *Multi-source Brand Product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of October 1, 2026 and subject to change.